human igg2

Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).

Human IgG2 kappa Isotype Control is a monoclonal antibody serving as an isotype control specific to human IgG2κ antibodies [1].

Human IgG1 CH1-Human IgG2 Fc-Kappa Isotype control is the isotype control for Human IgG1 CH1+Human IgG2 Fc-Kappa antibody.

Brodalumab (AMG 827) is a human monoclonal IgG2 antibody targeting the interleukin 17 receptor (IL-17R), commonly used as an immunosuppressant in treating psoriasis.

Tarextumab (OMP-59R5), a fully human IgG2 monoclonal antibody targeting Notch2 3 receptors, demonstrates anti-tumor activity [1].

Ascrinvacumab (PF-03446962) is a highly humanized IgG2 monoclonal antibody against ALK-1 with a Kd value of 7 nM for human ALK1. It has an inhibitory effect on TGF-β and can be used to study hepatocellular carcinoma (HCC).

Befovacimab (BAY 1093884), a fully human monoclonal IgG2 antibody, binds to the tissue factor pathway inhibitor (TFPI). It is utilized in research for haemophilia A B [1].

Tafolecimab (IBI-306), a human IgG2 monoclonal antibody, specifically targets and binds to PCSK-9, thus inhibiting PCSK-9-mediated endocytosis of the LDL receptor. This action enhances the clearance of LDL-C, resulting in a decrease in LDL-C levels. Tafolecimab has potential applications in hypercholesterolemia research [1].

Eflepedocokin alfa is a recombinant fusion protein comprising human IL-22 fused with the human IgG2-Fc domain, exhibiting cell protective activity. It activates the IL-22 IL-22R-mediated signal transduction pathways, including STAT3, playing a critical role in immune response to bacterial infections. It enhances intestinal barrier function, boosts intestinal immunity, and facilitates tissue repair [1].

Glembatumumab is a fully human IgG2 monoclonal antibody targeting the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. It is a naked antibody to Glembatumumab vedotin and can be used to study antibody-activated molecule couplings (Glembatumumab vedotin).

Prezalumab (AMG 557) is a human IgG2 monoclonal antibody targeting ICOSL and BAFF, used for studying Sjogren's syndrome, cutaneous lupus erythematosus, psoriasis, systemic lupus erythematosus arthritis, and systemic lupus erythematosus (SLE).

Bapotulimab (BAY-1905254) is a fully human IgG2 antibody targeting the immunoglobulin-like domain-containing receptor 2 (ILDR2), and it exhibits antitumor and immunosuppressive effects [1].

Fulranumab, a human IgG2 monoclonal antibody targeting nerve growth factor (NGF), is utilized in pain research [1].

RG-6125 is a humanized antibody expressed in CHO cells, targeting CDH11 Cadherin-11. It features a huIgG2 heavy chain and a huκ light chain, with an estimated molecular weight (MW) of 145 kDa. For an isotype control, please refer to HumanIgG2kappa, Isotype Control.

AMG-820 is a human antibody targeting CSF-1R, inhibiting the binding of ligands CSF1 and IL34, and preventing subsequent ligand-induced receptor activation. For AMG-820's isotype control, refer to [Human IgG2 kappa, Isotype Control].